ReviewBritish journal of cancer2009
Methodological approaches in application of synthetic lethality screening towards anticancer therapy.
Review in British journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells.Cancers · 2019Article
- Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network.Scientific reports · 2018Article
- Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes.Medicine · 2016Article
- Use of RNAi screens to uncover resistance mechanisms in cancer cells and identify synthetic lethal interactions.Drug discovery today. Technologies · 2014Review
- High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H.Oncology reports · 2014Article
- Matching the power of high throughput screening to the chemical diversity of natural products.Natural product reports · 2013Review
- Identification of potential synthetic lethal genes to p53 using a computational biology approach.BMC medical genomics · 2013Article
- Synergistic Synthetic Biology: Units in Concert.Frontiers in bioengineering and biotechnology · 2013Review
- Strategies for the discovery and development of therapies for metastatic breast cancer.Nature reviews. Drug discovery · 2012Review
- ER-alpha-cDNA as part of a bicistronic transcript gives rise to high frequency, long term, receptor expressing cell clones.PloS one · 2012Article
- Studying synthetic lethal interactions in the zebrafish system: insight into disease genes and mechanisms.Disease models & mechanisms · 2012Review
- Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.Molecular medicine (Cambridge, Mass.) · 2011Review
- Genome-wide approaches to systematically identify substrates of the ubiquitin-proteasome pathway.Trends in biotechnology · 2010Review
- Decoding pooled RNAi screens by means of barcode tiling arrays.BMC genomics · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A promising direction in the development of selective less toxic cancer drugs is the usage of synthetic lethality concept. The availability of large-scale synthetic low-molecular-weight chemical libraries has allowed HTS for compounds synergistic lethal with defined human cancer aberrations in activated oncogenes or tumour suppressor genes. The search for synthetic lethal chemicals in human/mouse tumour cells is greatly aided by a prior knowledge of relevant signalling and DNA repair pathways, allowing for educated guesses on the preferred potential therapeutic targets. The recent generation of human/rodents genome-wide siRNAs, and shRNA-expressing libraries, should further advance this more focused approach to cancer drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.